A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide in Healthy Adult Volunteers Under Fasting Conditions

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to evaluate the relative bioavailability of Paddock Laboratories, Inc.'s test formulation of Moexipril/ Hydrochlorothiazide 15mg/25mg tablets with a reference formulation Uniretic®(Moexipril/ Hydrochlorothiazide) 15mg/25mg tablets, under fasting conditions.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Paddock Laboratories, Inc.
• Treatments: Hydrochlorothiazide; Moexipril

Criteria

Inclusion Criteria:

• Good health as determined by lack of clinically significant abnormalities in health assessments performed at screening

Exclusion Criteria:

• Positive test results for HIV or Hepatitis B or C

• History of allergy or sensitivity to Moexipril, Hydrochlorothiazide or related drugs